Skip to main content

Advertisement

Log in

A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy

Diabetology International Aims and scope Submit manuscript

Abstract

Objective

To identify the attenuating factor of glycated hemoglobin (HbA1c)-lowering effects of liraglutide in type 2 diabetes (T2D) patients over the long term.

Methods

Forty-six T2D patients received liraglutide-glimepiride combination therapy. Clinical characteristics were compared between the following two subgroups: the relapse group (≥0.4 % increase in HbA1c in 48 weeks compared to 12 weeks) and non-relapse group (remaining patients). A glucagon-loading test was performed to evaluate baseline endogenous insulin secretion.

Results

In the relapse group, significantly reduced HbA1c, as observed at 12 weeks, tended to increase at 24 and 48 weeks. In the non-relapse group, reduced HbA1c was maintained for 48 weeks. Body weight was decreased at 12 weeks and then recovered at 48 weeks in both groups. Baseline BMI was significantly higher in the relapse group than in the non-relapse group. Age, HbA1c, duration of diabetes, fasting C-peptide, daily glimepiride dose and the duration of glimepiride treatment were comparable between both groups. Multiple logistic regression analysis revealed that baseline BMI was independently associated with the relapse group.

Conclusion

A higher BMI is the leading factor for attenuating long-term glycemic control by liraglutide in T2D patients undergoing sulfonylurea-based therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. International Diabetes Federation. IDF Diabetes Atlas Sixth Edition Poster Update 2014 (online), available from http://www.idf.org/diabetesatlas/update-2014 (accessed 2015-04-20).

  2. Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell. 2013;152:673–84.

    Article  CAS  PubMed  Google Scholar 

  3. UK Prospective Diabetes Study. UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34. Lancet. 1998;352:854–65.

    Article  Google Scholar 

  4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705.

    Article  CAS  PubMed  Google Scholar 

  5. Harder H, Nielsen L, Tu DT, et al. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004;27:1915–21.

    Article  CAS  PubMed  Google Scholar 

  6. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27:1335–42.

    Article  CAS  PubMed  Google Scholar 

  7. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Management of Hyperglycemia in Type2 Diabetes. A patient- Centered Approach. Diabetes Care. 2015;2015(38):140–9.

    Google Scholar 

  8. Takabe M, Matsuda T, Hirota Y, et al. C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment. Diabetes Res Clin Pract. 2012;98:e32–5.

    Article  CAS  PubMed  Google Scholar 

  9. Usui R, Yabe D, Kuwata H, Fujiwara S, et al. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function. J Diabetes Investig. 2013;4:585–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Toyoda M, Yokoyama H, Abe K, et al. Predictors of response to liraglutide in Japanese type 2 diabetes. Diabetes Res Clin Pract. 2014;106:451–7.

    Article  CAS  PubMed  Google Scholar 

  11. Imai K, Tsujimoto T, Goto A, et al. Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes. Diabetol Metab Syndr. 2014;6:110.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Inoue K, Maeda N, Fujishima Y, et al. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study. Diabetol Metab Syndr. 2014;6:95.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Nauck M, Frid A, Hermansen K, et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab. 2013;15:204–12.

    Article  CAS  PubMed  Google Scholar 

  14. Kubota A, Yabe D, Kanamori A, et al. Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea. J Diabetes Investig. 2014;5:445–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 2010;53:450–467.

  16. Kozawa J, Inoue K, Iwamoto R, et al. Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity. J Diabetes Investig. 2012;3:294–7.

    Article  CAS  PubMed  Google Scholar 

  17. Fujishima Y, Maeda N, Inoue K, et al. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol. 2012;14(11):107.

    Article  Google Scholar 

  18. Lapolla A, Frison V, Bettio M, et al. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy. Clin Ther. 2015;37:574–84.

    Article  PubMed  Google Scholar 

  19. Degn KB, Juhl CB, Sturis J, et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187–94.

    Article  CAS  PubMed  Google Scholar 

  20. Kramer CK, Zinman B, Choi H, et al. The impact of chronic liraglutide therapy on glucagon secretion in type 2 diabetes: insight from the LIBRA trial. J Clin Endocrinol Metab. 2015;100:3702–9.

    Article  CAS  PubMed  Google Scholar 

  21. Seino Y, Rasmussen MF, Clauson P, et al. The once-daily human glucagon-like peptide-1 analog, liraglutide, improves β-cell function in Japanese patients with type 2 diabetes. J Diabetes Investig. 2012;3:388–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Hermansen K, Bækdal TA, Düring M, et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab. 2013;15:1040–8.

    Article  CAS  PubMed  Google Scholar 

  23. Ahrén B, Foley JE, Ferrannini E, et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2010;33:730–2.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Tajiri Y, Tsuruta M, Ohki T, et al. Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan. Endocr J. 2012;59:197–204.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Takeshi Yamamoto or Tomoyasu Fukui.

Ethics declarations

Ethics policy

All procedures followed were in accordance with the Institutional Review Board for Clinical Research at the Showa University of Medicine and with the Helsinki Declaration of 1964 and later versions. Informed consent was obtained from all patients for being included in the study.

Conflict of interest

Takeshi Yamamoto, Tomoyasu Fukui, Akiko Higuchi, Makoto Ohara, and Toshiyuki Hayashi declare that they have no conflicts of interest. Tsutomu Hirano received a research grant from Eli Lilly Japan K.K. and Takeda Pharmaceutical Co., Ltd., and received lecture fees from Astra Zeneca, Mitsubishi Tanabe Pharma Corp., and MSD K.K.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 260 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yamamoto, T., Fukui, T., Higuchi, A. et al. A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy. Diabetol Int 7, 425–431 (2016). https://doi.org/10.1007/s13340-016-0269-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-016-0269-8

Keywords

Navigation